OverviewSuggest Edit

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.
TypePublic
Founded2010
HQCambridge, US
Websitefoundationmedicine.com

Latest Updates

Employees (est.) (Sept 2017)535
Job Openings132
Revenue (FY, 2017)$152.9 M(+31%)
Share Price (Jul 2018)$137

Key People/Management at Foundation Medicine

Michael J. Pellini

Michael J. Pellini

President & CEO & Board Director
Steven J. Kafka

Steven J. Kafka

Chief Business Officer
Alexis Borisy

Alexis Borisy

Co - Founder & Chairman of the Board
Vincent A. Miller

Vincent A. Miller

SVP, Clinical Development
Show more

Foundation Medicine Office Locations

Foundation Medicine has offices in Cambridge, Morrisville and Palo Alto
Cambridge, US (HQ)
150 Second St
Morrisville, US
7010 Kit Creek Rd
Palo Alto, US
525 University Ave #100
Show all (3)

Foundation Medicine Financials and Metrics

Foundation Medicine Revenue

Foundation Medicine's revenue was reported to be $152.90 m in FY, 2017
USD

Revenue (Q2, 2018)

38.7m

Net income (Q2, 2018)

(33.4m)

EBIT (Q2, 2018)

(32.1m)

Market capitalization (31-Jul-2018)

5.1b

Closing stock price (31-Jul-2018)

137.0

Cash (30-Jun-2018)

53.4m
Foundation Medicine's current market capitalization is $5.1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

29.0m61.1m93.2m116.9m152.9m

Revenue growth, %

111%53%25%

Cost of goods sold

11.7m27.4m36.7m53.0m

Gross profit

17.3m33.6m56.5m63.9m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

8.2m11.5m14.5m16.4m19.3m22.5m25.4m30.4m28.2m29.4m26.3m35.0m42.7m52.8m38.7m

Cost of goods sold

2.9m5.3m6.6m7.5m8.9m9.0m9.1m10.0m11.5m14.7m17.1m

Gross profit

5.4m6.2m7.9m8.9m10.4m13.5m16.3m20.4m16.8m14.7m9.2m

Gross profit Margin, %

65%54%54%54%54%60%64%67%59%50%35%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

124.3m72.1m117.8m63.6m71.4m

Accounts Receivable

6.3m9.9m7.4m8.2m20.0m

Prepaid Expenses

992.0k2.9m6.5m9.1m

Inventories

1.8m4.8m8.0m10.4m13.2m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(42.9m)(52.2m)(89.6m)(113.2m)(161.5m)

Depreciation and Amortization

5.0m8.2m10.6m15.9m18.5m

Inventories

(960.0k)(3.0m)(3.3m)(2.4m)(2.6m)

Accounts Payable

1.7m3.1m(1.6m)5.1m8.4m
USDY, 2018

Financial Leverage

-22.7 x
Show all financial metrics

Foundation Medicine Operating Metrics

Foundation Medicine's Customers was reported to be 30 in FY, 2016.
FY, 2016

Customers

30

Facilities

4

Products

5
Show all operating metrics

Foundation Medicine Revenue Breakdown

Embed Graph

Foundation Medicine revenue breakdown by geographic segment: 91.2% from United States and 8.8% from Other

Foundation Medicine Online and Social Media Presence

Embed Graph

Foundation Medicine News and Updates

UPDATE 1-Bayer to work with Foundation Medicine on cancer patient screening

* Genetic sequencing test seen as vital to secure market uptake

Global $85.5 Billion Precision Medicine (Diagnostics/Therapeutics) Market to 2025 - Key Players are GE Healthcare; Abbott Lab, Precision Biologics, Foundation Medicine, Illumina and IBM Watson

DUBLIN, Nov. 16, 2018 /PRNewswire/ -- The "Precision Medicine (Diagnostics/Therapeutics) Market Analysis Report By Application (Genetic Tests, Esoteric Tests, Pharmaceuticals, Medical Devices), By End Use, And Segment Forecasts, 2018 - 2025" report has been added to...

UPDATE 2-Roche pays $2.4 bln for rest of cancer expert Foundation Medicine

* Echoes past biotech buy-outs at Flat Iron and Genentech (Adds more on personalised cancer care, analyst comment)

UPDATE 1-Roche to pay $2.4 bln to buy rest of Foundation Medicine

ZURICH, June 19 (Reuters) - Swiss drugmaker Roche Holding AG has agreed to pay $137 per share to buy the rest of Foundation Medicine (FMI), a $2.4 billion transaction that values the U.S. genomic profiling group at $5.3 billion, the partners said on Tuesday.

Foundation Medicine Blogs

Partnerships Are Paving the Way for Improved Patient Options

This article was originally published on LinkedIn. Over the past ten years, there has been a fundamental shift in the way cancer is being treated. Access…

A Year of Change and an Exciting Chapter Ahead

This article was originally published on LinkedIn. December is always a busy time. Suddenly everyone seems to be filled with a sense of urgency and purpose…

ASH 2019: Can Rapid Precision Medicine Help Older Adults With AML?

When someone is diagnosed with acute myeloid leukemia (AML), doctors typically initiate treatment within 24-48 hours of diagnosis given the aggressive nature of the disease.

Breast cancer – a very personal history and an even more personalized future

This article was originally published on LinkedIn. As I sat down to write this latest post, I was suddenly struck by how little I have written…

CTOS 2019: Navigating the sarcoma maze with CGP

Every cancer presents its challenges, but sarcomas are particularly troublesome. They are tricky to diagnose and have few treatment options. Sarcomas are a group of rare…

ESMO 2019: Comprehensive Genomic Profiling Leverages Data Insights to Improve Patient Care

As scientists worldwide continue to pioneer breakthroughs and change the way we understand and treat advanced cancer, it’s important to stay connected so we can…
Show more

Foundation Medicine Frequently Asked Questions

  • When was Foundation Medicine founded?

    Foundation Medicine was founded in 2010.

  • Who are Foundation Medicine key executives?

    Foundation Medicine's key executives are Michael J. Pellini, Steven J. Kafka and Alexis Borisy.

  • How many employees does Foundation Medicine have?

    Foundation Medicine has 535 employees.

  • What is Foundation Medicine revenue?

    Latest Foundation Medicine annual revenue is $152.9 m.

  • What is Foundation Medicine revenue per employee?

    Latest Foundation Medicine revenue per employee is $285.8 k.

  • Who are Foundation Medicine competitors?

    Competitors of Foundation Medicine include Flatiron Health, Myriad Genetics and Boston Health Economics.

  • Where is Foundation Medicine headquarters?

    Foundation Medicine headquarters is located at 150 Second St, Cambridge.

  • Where are Foundation Medicine offices?

    Foundation Medicine has offices in Cambridge, Morrisville and Palo Alto.

  • How many offices does Foundation Medicine have?

    Foundation Medicine has 3 offices.